Key Segmentation
By Phase
-
Phase III
-
Phase II
-
Phase I
-
Phase IV
By Omics Type
-
Genomics
-
Transcriptomics
-
Proteomics
-
Multi-Omics
By Application
-
Oncology
-
Rare Genetic Diseases
-
Neurology
-
Cardiovascular Diseases
By End User
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Contract Research Organizations
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Phase III segment held approximately 54.50% share in 2025.
North America held the largest share of the Omics-Based Clinical Trials Market in 2025, at approximately 38.00%.
Rising personalized medicine adoption combined with broader multi-omics methodology integration is the major growth factor.
The Omics-Based Clinical Trials Market was valued at USD 33.93 Billion in 2025.
The Omics-Based Clinical Trials Market is expected to grow at a CAGR of 8.33% from 2026 to 2035.